bioAffinity Technologies, Inc. (NASDAQ:BIAFW)
| Market Cap | 8.49M+164.9% |
| Revenue (ttm) | 5.90M-23.2% |
| Net Income | -15.19M-29.9% |
| EPS | -3.35+61.2% |
| Shares Out | 4.53M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 6,567 |
| Open | 0.47 |
| Previous Close | 0.55 |
| Day's Range | 0.21 - 0.47 |
| 52-Week Range | 0.21 - 0.47 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 18, 2026 |
About BIAFW
bioAffinity Technologies, Inc. engages in developing non-invasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. The company operates through two segments: Diagnostic Research and Development; and Laboratory Services. The company offers CyPath lung which uses flow cytometry technology to detect and analyze cell populations in a person's sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cancer-related cells that have shed from a lung tumor. bioAffinity Technologies, Inc. was incorporated in 2014 and is based in San Antonio, Texas.
$BIAFW stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in BIAFW holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by BIAFW's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
BIAFW Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New BIAFW patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to BIAFW from public contracts
Source: USAspending.gov
BIAFW Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from BIAFW’s recent data — informational, not investment advice
Recent Insider Activity
No Form 4 filings in the last 90 days.